Guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients
|
|
- Tracey Dawson
- 5 years ago
- Views:
Transcription
1 Cumbria, Nrthumberland, Tyne & Wear Area Team Guideline fr the use f granulcyte-clny stimulating factr (G-CSF) in adult nclgy and haematlgy patients Dcument Cntrl Prepared By Issue Date Apprved By Review Date Versin Cntributrs Cmments/ Amendment S Williamsn / Chemtherapy W Hrsley Grup Calum Plwart S.Williamsn Chemtherapy Grup Gail Jnes Updated sectin 3.5 S Williamsn Chemtherapy Grup Will Hrsley Inclusin f Lipegfilgrastim and assciated guidance Acknwledgements This guidance has been based upn Yrkshire Cancer Netwrk plicy, whse authr David Thmsn, kindly agreed fr the plicy t becme basis f lcal NHS England/ Netwrk Guidance, fllwing changes in cmmissining arrangements fr GCSF prducts frm 1 st April 2014 GCSF Guidelines June 2014 v1.41 Page 1 f 11 Apprved Expiry 30th June 2016
2 i Table f Cntents I TABLE OF CONTENTS INTRODUCTION INDICATIONS FOR G-CSF USE CRITERIA FOR G-CSF PRESCRIBING CRITERIA 1A: CHEMOTHERAPY SUPPORT FOR REGIMENS WITH CURATIVE/ RADICAL INTENT: PRIMARY PROPHYLAXIS (FIRST AND SUBSEQUENT CYCLE USE) CRITERIA 1B: CHEMOTHERAPY SUPPORT FOR REGIMENS WITH CURATIVE/ RADICAL INTENT: SECONDARY PROPHYLAXIS (PROPHYLACTIC USE IN SUBSEQUENT CYCLES AFTER INITIAL EPISODE(S) OF SEVERE AND/ OR FEBRILE NEUTROPENIA) CRITERIA 2: SUPPORTIVE THERAPY FOR SEVERE NEUTROPENIC SEPSIS CRITERIA 3: PERIPHERAL BLOOD STEM CELL MOBILISATION Backgrund Dsing CRITERIA 4: PERIPHERAL BLOOD STEM CELL TRANSPLANTATION Pst peripheral bld stem cell transplantatin Duratin f treatment CRITERIA 5: GRAFT FAILURE POST STEM CELL TRANSPLANTATION CRITERIA 4: CLINICAL TRIALS WHERE APPROPRIATE AND STATED WITHIN THE TRIAL PROTOCOL APPROVAL TO PRESCRIBE GCSF FOR ALL INDICATIONS EXCEPT IN PERIPHERAL BLOOD STEM CELL MOBILISATION FOR PERIPHERAL BLOOD STEM CELL MOBILISATION PRESCRIBING G-CSF REFERENCES GCSF Guidelines June 2014 v1.41 Page 2 f 11 Apprved Expiry 30th June 2016
3 1 Intrductin Chemtherapy-induced febrile neutrpenia is a serius side effect f cancer treatment and is nt nly a majr risk factr fr infectin-related mrbidity and mrtality, but is als a significant dse-limiting txicity. Patients develping severe (grade 3/4) r febrile neutrpenia (FN) during chemtherapy frequently receive dse reductins and/r delays t their chemtherapy schedule. This may impact n the success f treatment, particularly when treatment intent is either curative r t prlng survival (1). One methd f reducing the incidence f severe r FN is thrugh the prphylactic use f G-CSF. G-CSF may als be used t increase neutrphils in thse patients experiencing severe prlnged neutrpenic episdes after chemtherapy treatment r in thse patients requiring mbilisatin f peripheral bld stem cells fr harvesting. There are currently 3 branded CSFs available n the UK market. There is very little direct cmparative data t enable an bjective assessment between agents t be made. There are several bi-similar GCSF brands available, e.g. Ratigrastim, Tevagrastim and Zarzi. These are bi-similar filgrastim i.e. the prtein structure is very similar t the riginal Neupgen versin f filgrastim. The natinal bne marrw transplant service has recmmended against the use f bisimilar fr PBSC until further evidence f effectiveness in this setting is available. NHS England recmmends the use f Bisimilars as first chice GCSF in all settings where the Neupgen brand f filgrastim wuld therwise have been used. The chice f use f bisimilar in place f standard GCSF shuld be a lcal cmmissining decisin but shuld generally be the lwest price. NHS England des nt recmmend rutine use f lnger-acting pegalyted GCSFs such as pegfilgrastim (Neupgen ) and Lipegfilgrastim (Lnquex ). An exceptin is made fr a limited number f specific situatins. Where a lnger- acting GCSF is required prescribers shuld select the mst cst-effective treatment which in mst cases will be the preparatin with the lwest acquisitin cst. The aim f this guideline is t prvide evidence-based guidance t clinicians and ther health prfessinals n the ratinal prescribing and safe administratin f G-CSF and t prmte harmnisatin f prescribing practice. (Please nte: these guidelines d nt apply t acute leukaemia r paediatric patients fllw guidelines stated within the relevant trial prtcl). 2 Indicatins fr G-CSF use G-CSF may be prescribed fr the fllwing indicatins, accrding t the criteria fr G-CSF prescribing utlined in sectin 3: a. Chemtherapy supprt fr regimens with curative/radical intent (primary/secndary prphylaxis). b. Supprtive therapy fr severe neutrpenic sepsis. c. Peripheral bld stem cell mbilisatin. d. Clinical trials where apprpriate and stated within the trial prtcl. Nte: Patients receiving palliative chemtherapy shuld nt generally receive prphylactic G-CSF fr chemtherapy supprt manipulatins t minimise neutrpenic episdes and sepsis must initially include dse delay and/r dse reductin (refer t individual chemtherapy prtcls fr guidance) as there is n evidence that dse maintenance r escalatin imprves clinically imprtant utcmes. The use f G-CSF in this setting must be apprved n an individual patient basis accrding t lcal trust plicies fr named patient apprval f expenditure. GCSF Guidelines June 2014 v1.41 Page 3 f 11 Apprved 16 June 2014 Expiry 16 June 2016
4 3 Criteria fr G-CSF prescribing 3.1 Criteria 1A: Chemtherapy supprt fr regimens with curative/ radical intent: Primary prphylaxis (first and subsequent cycle use) Chemtherapy patients shuld nt rutinely be prescribed prphylactic G-CSF after their first cycle f chemtherapy except in the circumstances described belw. Primary prphylaxis may nly be cnsidered fr patients with a high verall risk (> 20%) f febrile neutrpenia as defined belw: Patients receiving myeltxic chemtherapy with curative r radical intent (including adjuvant/neadjuvant chemtherapy) and which has a dcumented incidence rate f FN f > 20% (see table 1) Regimen Tumur type Dcumented FN risk Reference DHAP NHL (relapsed) 48% (1), (2) ESHAP/ FLUDAP NHL Hdgkins disease Multiple Myelma 30% (1), (2) (all relapsed) All Dcetaxel-based regimens Breast (Ne-adjuvant) Breast (adjuvant) 22-36% (3), (4) (includes FEC-T) CODOX-M/ IVAC (+/-R) Burkitts Lymphma >50% (5) Mini-BEAM Hdgkins disease (relapsed) 54% (6) Table 1: Regimens with FN rate f >20% Primary prphylaxis may als be cnsidered in: Patients receiving myeltxic chemtherapy with curative/radical intent (including adjuvant/neadjuvant chemtherapy) and which has a dcumented incidence rate f FN f 10 20% (see table 2) AND any ne r mre f the fllwing pre-dispsing patient risk factrs (1): Patient age > 65 years Pr perfrmance status Previus episdes f febrile neutrpenia Extensive prir treatment including large radiatin prts Administratin f cmbined chemraditherapy Bne marrw invlvement by tumur-prducing cytpenias Pr nutritinal status The presence f pen wunds r active infectins Mre advanced cancer Other serius c-mrbidities GCSF Guidelines June 2014 v1.41 Page 4 f 11 Apprved 16 June 2014 Expiry 16 June 2016
5 Regimen Epi-CMF (Epi nly) BEP EP Carb/Etpside POMB-ACE TIP VIP Stanfrd V CHOP 21 FMD IVE R-CHOP 21 Tumur type Breast Hdgkins disease NHL NHL NHL (relapsed) NHL Table 2: Regimens with FN rate f 10-20% The G-CSF f chice fr primary prphylaxis in CNTW Area Team is daily G-CSF in the frm f the bisimilar Filgrastim. Occasinally the use f a lnger-acting pegylated G-CSF as primary prphylaxis may be cnsidered e.g. patients wh cannt be taught r are incapable t self-inject r fr whm there is nt a suitable carer available t inject with daily G-CSF. GCSF dsage and administratin guidelines in the prphylactic setting. Because the kinetics f myeltxicity and recvery f bne marrw functin vary between cyttxic agents and regimens, universal recmmendatins n this subject cannt be made. There is sme evidence that treatment sn after chemtherapy may be mre beneficial than later, althugh, f curse, G-CSF is cntraindicated within 24 hurs f chemtherapy, when stimulatin f prgenitr cells in the presence f cyttxics may actually wrsen the myeltxicity f the regimen. Fr cyttxic drugs with a lng half life, a lnger interval may be required t avid increased myeltxicity. A reasnable starting pint fr GCSF is t start nt less than 24 hurs and nt mre than 72 hurs after cyttxic treatment is cmpleted. This ensures that the stimulus prvided is present at a time when the bne marrw is regenerative and able t respnd. G-CSF injectins shuld cntinue until the neutrphil cunt has recvered t > 1.0 x 10 9 /L n tw cnsecutive days. This will nrmally require a minimum f 5 days f treatment, althugh cnsideratin shuld be given t a minimum f 7 days fr mre myelsuppressive regimens studies lking at NHL patients receiving myelsuppressive chemtherapy shwed that patients receiving 5 dses f G-CSF had abut 3 times the risk f febrile neutrpenia and hspitalizatin than thse wh received a 10 day curse (7,8). It is nt expected that every patient has serial FBC tests, rather that adjustments t the duratin f therapy are made based n clinical expertise and past respnse f the patient t GCSF. See table 3 belw fr GCSF dsage and administratin guidelines in the prphylactic setting. GCSF Guidelines June 2014 v1.41 Page 5 f 11 Apprved 16 June 2014 Expiry 16 June 2016
6 Drug Bisimilar Filgrastim (Zarzi ) Lipegfilgrastim (Lnquex ) r Pegfilgrastim (Neulasta ) Patient weight <78kg 78kg Dse 30MU 48MU Rute Frequency sc Once daily All 6mg sc Single dse Weekly chem cycle Days t prescribe (see nte 1) 3 2 weekly weekly chem chem cycle cycle 4 weekly chem cycle Initiate G-CSF 24-72hrs after administratin f chemtherapy unless therwise specified in the chemtherapy prtcl Cntinue until after nadir and ANC 1.0 X 10 9 /L r as per chemtherapy prtcl. Nt recmm ended One dse is recmmended fr each chemtherapy cycle, administered apprximately 24 hurs fllwing cyttxic chemtherapy Table 3: G-CSF Dsage and Administratin Guidelines fr patients fulfilling criteria 1A/1B Nte 1: The ptimal timing and duratin f G-CSF administratin in the prphylactic setting has nt been defined hwever the recmmendatins abve shuld be cnsidered as a guide. GCSF Guidelines June 2014 v1.41 Page 6 f 11 Apprved 16 June 2014 Expiry 16 June 2016
7 3.2 Criteria 1B: Chemtherapy supprt fr regimens with curative/ radical intent: Secndary prphylaxis (prphylactic use in subsequent cycles after initial episde(s) f severe and/ r febrile neutrpenia) Secndary prphylaxis shuld nly be cnsidered in patients: Receiving myeltxic chemtherapy with curative r radical intent And where further treatment delays r dse reductins may cmprmise the intended treatment utcme, fr example in any ne f the fllwing circumstances: Where tw r mre dse reductins have ccurred due t neutrpenia r febrile neutrpenia after a chemtherapy cycle Where chemtherapy treatment is delayed n tw r mre ccasins due t neutrpenia r febrile neutrpenia Nte: Dse mdificatins will be a reasnable alternative in many clinical situatins. Secndary prphylaxis may nly be cnsidered after ne delay in chemtherapy treatment r ne dse reductin due t an episde f neutrpenia r febrile neutrpenia fr the fllwing patient grups where dse reductin/ dse delay wuld cmprmise disease free r verall survival: Adjuvant breast cancer Lymphma (nn-hdgkins lymphma r hdgkins disease) malignancies Ne-adjuvant chemtherapy Limited stage small cell lung cancer Radical chemradiatin (where delay r missin f chemtherapy treatment during cncurrent therapy may have a negative impact n disease cntrl) Multiple myelma The G-CSF f chice fr secndary prphylaxis in CNTW is daily G-CSF in the frm f the bisimilar Filgrastim. Occasinally the use f a lnger-acting pegylated G-CSF as primary prphylaxis may be cnsidered e.g. patients wh cannt be taught r are incapable t self-inject r fr whm there is nt a suitable carer available t inject with daily G-CSF. Refer t table 3 fr GCSF dsage and administratin guidelines in the prphylactic setting. GCSF Guidelines June 2014 v1.41 Page 7 f 11 Apprved 16 June 2014 Expiry 16 June 2016
8 3.3 Criteria 2: Supprtive therapy fr severe neutrpenic sepsis G-CSF must nt be rutinely prescribed fr the treatment f patients with uncmplicated febrile neutrpenia r afebrile neutrpenia. G-CSF may nly be prescribed fr the supprtive treatment f patients with severe febrile neutrpenia in scenaris as defined belw: Prfund febrile neutrpenia: defined as abslute neutrphil cunt (ANC) < 0.1 x 10 9 /L and patient febrile And any ne f the fllwing prgnstic factrs that are predictive f pr clinical utcme: Clinically unwell with signs such as hyptensin, rgan dysfunctin etc indicating ptential risk f septic shck Expected prlnged duratin f neutrpenia (> 10 days) Persistent pyrexia despite apprpriate antibitics/antifungals Uncntrlled primary disease Pneumnia Prven r suspected invasive fungal infectin Patients treated with a lnger-acting pegylated G-CSF shuld nt be treated with additinal G-CSF. In additin, there is currently a lack f evidence fr therapeutic (rather than prphylactic) use f lnger-acting G-CSF (3). Refer t table 4 fr GCSF dsage and administratin guidelines in the neutrpenic sepsis setting. Table 4: G-CSF Dsage and Administratin Guidelines fr patients fulfilling criteria 2 Patient Drug Weight r BSA Dsage Rute Frequency Bisimilar Filgrastim (Zarzi) <78kg 78kg 30MU 48MU sc Once daily Criteria fr stpping treatment Stp G-CSF nce ANC > 0.5 x 10 9 /L fr at least tw cnsecutive days Nte: Lnger-acting Pegylated G-CSF is nt apprved fr use in this setting GCSF Guidelines June 2014 v1.41 Page 8 f 11 Apprved 16 June 2014 Expiry 16 June 2016
9 3.4 Criteria 3: Peripheral bld stem cell mbilisatin Backgrund Guidelines fr apprval f bisimilars have been issued by the EMEA (9) and vary accrding t the prduct. In general, the apprval f bisimilars is based n the demnstratin f equivalent efficacy and safety t the innvatr prduct in cmparative studies. In the case f G-CSF, equivalence has t be demnstrated in the prphylaxis f severe cyttxic chemtherapy-induced neutrpenia and extraplatin f efficacy t the ther indicatins f the reference prduct (e.g. mbilizatin f stem cells) is then allwed. Because there is a limited clinical database n apprval f a bisimilar ( patients app.), pharmacvigilance is becming essential, particularly as nly six-mnth fllw up is needed fr safety in registratin studies. Therefre the EBMT recmmends evaluatin f efficacy and safety data fr stem cell mbilizatin befre using bisimilar G-CSF in healthy dnrs. This can nly be btained by perfrming clinical trials with an adequate number f stem cell mbilizatin prcedures with adequate fllw up in autlgus cnditins. Until studies have been perfrmed t prvide the required efficacy and safety data, the EBMT des nt recmmend the use f bisimilar G-CSFs fr mbilizatin f stem cells in healthy dnrs fr stem cell transplantatin (10). The same advice shuld be cnsidered fr autlgus stem cell mbilisatin Dsing Fr patients nt in a study, Lengrastim (GRANOCYTE ) shuld be used at the dsing schedule in the manufacturers SPC. Lengrastim (GRANOCYTE ) shuld be prescribed t all patients underging harvesting f peripheral bld stem cells. Nte: Lnger-acting Pegylated G-CSF is nt apprved fr use in this setting. 3.5 Criteria 4: Peripheral bld stem cell transplantatin Pst peripheral bld stem cell transplantatin If indicated patients shuld receive bisimilar Filgrastim at the daily dsing schedule in the manufacturers SPC accrding t patients weight. Nte pst-autgraft patients are at >20% FN risk, use f GCSF has the ptential t save 1-2 bed days per transplant Duratin f treatment Autlgus transplants - Stp the G-CSF after 2 cnsecutive days f neutrphils >1.0 x 10 9 /l. Nte: Lnger-acting Pegylated G-CSF is nt apprved fr use in this setting. GCSF Guidelines June 2014 v1.41 Page 9 f 11 Apprved 16 June 2014 Expiry 16 June 2016
10 3.6 Criteria 5: Graft failure pst stem cell transplantatin G-CSF may be prescribed t patients receiving chemtherapy with radical r curative intent wh are being treated within a clinical trial and where G-CSF is recmmended r allcated as part f the trial prtcl. In the setting f graft failure pst stem cell transplantatin (i.e. after satisfactry engraftment, neutrpenia develps), supprt with a trial f haematpietic grwth factrs may reslve the graft failure. 3.7 Criteria 4: Clinical trials where apprpriate and stated within the trial prtcl G-CSF may be prescribed t patients receiving chemtherapy with radical r curative intent wh are being treated within a clinical trial and where G-CSF is recmmended r allcated as part f the trial prtcl. The G-CSF brand, dsage and administratin schedule used within a clinical trial shuld be that recmmended within the trial prtcl. 4 Apprval t prescribe GCSF 4.1 Fr all indicatins EXCEPT in peripheral bld stem cell mbilisatin Unless a regimen listed in sectins r specified in a chemtherapy prtcl that has been agreed by the Netwrk Chemtherapy Grup a cnsultant nclgist/haematlgist, assciate specialist r specialist registrar must authrise G-CSF treatment accrding t the abve recmmendatins but it may be prescribed by any member f the clinical team and the indicatin must be dcumented in the patient s medical ntes. 4.2 Fr peripheral bld stem cell mbilisatin Any member f the haematlgy medical team may prescribe G-CSF accrding t the apprpriate prtcl fr the particular patient. 4.3 Prescribing G-CSF In rder t ensure that the crrect prduct is administered, it is vital t specifiy the brand f GCSF required n the prescriptin. We wuld suggest prescribing by brand name nly. GCSF Guidelines June 2014 v1.41 Page 10 f 11 Apprved 16 June 2014 Expiry 16 June 2016
11 5 References (1) Aapr et al Update f EORTC guidelines fr the use f granulcyte-clny stimulating factr t reduce the incidence f chemtherapy-induced febrile neutrpenia in adult patients with lymphprliferative disrders and slid tumurs. Eur J Cancer 47 (2001): (2) Smith et al Update f Recmmendatins fr the Use f White Bld Cell Grwth Factrs: An Evidence-Based Clinical Practice Guideline. J Clin Oncl July ; 24 (19): (3) Natinal Cmprehensive Cancer Netwrk (NCCN) Clinical Practice Guidelines in Onclgy (2011). Myelid Grwth Factrs. V.I.2011 (4) MacDermtt, C. Febrile Neutrpenia in patients receiving adjuvant/ neadjuvant dcetaxel fr breast cancer Audit f Bradfrd Ryal Infirmary experience. Data n file. Octr 2011 (5) Mead, GM, et al. An internatinal evaluatin f CODOX-M and CODOX-M alternating with IVAC in adult Burkitts lymphma: results f United Kingdm Lymphma Grup LY06 study. Ann Oncl, (8): p (6) Clwill R, et al. Mini-BEAM as salvage therapy fr relapsed r refractry Hdgkin's disease befre intensive therapy and autlgus bne marrw transplantatin. J Clin Oncl February 1, 1995 vl. 13 n (7) Sctt, SD et al; J Manag Care Pharm 2003; 9: (8) Weycker, D et al; Prc ASCO 2004; 23: 613 Abstract 6731 (9) EMEA Cmmittee Fr Medicinal Prducts Fr Human Use (CHMP); Annex T Guideline On Similar Bilgical Medicinal Prducts Cntaining Bitechnlgy-Derived Prteins As Active Substance: On-Clinical And Clinical Issues - Guidance On Similar Medicinal Prducts Cntaining Recmbinant Granulcyte-Clny Stimulating Factr; 2006 (10) EBMT Stance n the Apprval f a G-CSF Bisimilar, 2009 (11) (Lnquex ) lipegfilgrastim Summary prduct Characteristics May 2013 (data n file) GCSF Guidelines June 2014 v1.41 Page 11 f 11 Apprved 16 June 2014 Expiry 16 June 2016
Guideline for the use of granulocyte-colony stimulating factor (G-CSF) in adult oncology and haematology patients
Guideline fr the use f granulcyte-clny stimulating factr (G-CSF) in adult nclgy and haematlgy patients Dcument Cntrl Prepared By Issue Date Apprved By S Williamsn / W Hrsley 14.02.14 S.Williamsn 11.03.14
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment r prphylaxis. Evidence supprting this guidance is detailed belw.
More informationIntravenous Vancomycin Use in Adults Intermittent (Pulsed) Infusion
Intravenus Vancmycin Use in Adults Intermittent (Pulsed) Infusin Backgrund This plicy cvers the use f intravenus vancmycin prescribed as an intermittent (pulsed) infusin. This can be used fr treatment
More informationCommissioning Policy: South Warwickshire CCG (SWCCG)
Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding
More informationCancer Association of South Africa (CANSA)
Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.
More informationCONSENT FOR KYBELLA INJECTABLE FAT REDUCTION
CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,
More informationFolotyn (pralatrexate)
Fltyn (pralatrexate) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/2018TBD03/01/2017 POLICY A. INDICATIONS The indicatins
More informationSolid Organ Transplant Benefits to Change for Texas Medicaid
Slid Organ Transplant Benefits t Change fr Texas Medicaid Infrmatin psted February 13, 2015 Nte: All new and updated prcedure cdes and their assciated reimbursement rates are prpsed benefits pending a
More informationA Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.
SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument
More informationAnnex III. Amendments to relevant sections of the Product Information
Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t
More informationMedical Policy Title: HDC & Autologous ARBenefits Approval: 02/08/2012
Medical Plicy Title: HDC & Autlgus ARBenefits Apprval: 02/08/2012 Stem&/r Prgenitr Cell Supprt, Germ Cell Tumrs Effective Date: 01/01/2013 Dcument: ARB0416:01 Revisin Date: 10/24/2012 Cde(s): 38230, Bne
More information2017 Optum, Inc. All rights reserved BH1124_112017
1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases
More informationWidening of funding restrictions for rituximab and eltrombopag
20 February 2014 Widening f funding restrictins fr rituximab and eltrmbpag PHARMAC is pleased t annunce the apprval f prpsals t widen the restrictin n rituximab use in DHB hspitals and expand the funding
More informationSpecifically, on page 12 of the current evicore draft, we find the statement:
Octber 23, 2016 evicre Healthcare Attn: Dr Greg Allen 400 Buckwalter Place Bulevard Blufftn, SC 29910 RE: evicre Draft Onclgy Imaging Guidelines, v 19.0 Gentlepersns: Prstate Cancer Internatinal is a nt-fr-prfit
More informationWARNING: FATAL AND SERIOUS TOXICITIES: SEVERE DIARRHEA AND CARDIAC TOXICITIES
INDICATION FARYDAK (panbinstat) capsules, a histne deacetylase inhibitr, in cmbinatin with brtezmib and dexamethasne, is indicated fr the treatment f patients with multiple myelma wh have received at least
More informationBariatric Surgery FAQs for Employees in the GRMC Group Health Plan
Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select
More informationFrequently Asked Questions: IS RT-Q-PCR Testing
Questins 1. What is chrnic myelid leukemia (CML)? 2. Hw des smene knw if they have CML? 3. Hw is smene diagnsed with CML? Frequently Asked Questins: IS RT-Q-PCR Testing Answers CML is a cancer f the bld
More informationRelated Policies None
Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER
More informationGeneric Immunosuppressants in the Specialist Area of Transplantation Consensus on Implications and Practical Recommendations
Dear Clleague Generic Immunsuppressants in the Specialist Area f Transplantatin Cnsensus n Implicatins and Practical Recmmendatins Executive Summary Slid-rgan transplants are the best pssible treatment
More information1.11 INSULIN INFUSION PUMP MANAGEMENT INPATIENT
WOMEN AND NEWBORN HEALTH SERVICE CLINICAL GUIDELINES SECTION A: GUIDELINES RELEVANT TO OBSTETRICS AND GYNAECOLOGY 1 STANDARD PROTOCOLS 1.11 INSULIN INFUSION PUMP MANAGEMENT - INPATIENT Authrised by: OGCCU
More informationITP typically presents with the sudden appearance of a petechial rash, spontaneous bruising and/or bleeding in an otherwise well child.
Acute Immune Thrmbcytpenia Purpura (ITP) Backgrund Primary immune thrmbcytpenia (ITP) is an acquired immune mediated disrder characterised by islated thrmbcytpenia, defined as a peripheral bld platelet
More informationSUMMACARE COMMERCIAL MEDICATION REQUEST GUIDELINES. ANTI-OBESITY AGENTS Generic Brand HICL GCN Exception/Other QSYMIA 32515, 32744, 32746, 32745
Generic Brand HICL GCN Exceptin/Other NALTREXONE CONTRAVE ER 41389 /BUPROPION LORCASERIN BELVIQ 34733 PHENTERMINE PHENTERMINE 20691 20692 20693 20713 PHENTERMINE LOMAIRA 20715 PHENTERMINE/TO PIRAMATE GUIDELINES
More informationSwindon Joint Strategic Needs Assessment Bulletin
Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical
More informationPBTC-026: A Feasibility Study of SAHA Combined with Isotretinoin and Chemotherapy in Infants with Embryonal Tumors of the Central Nervous System
PBTC-026: A Feasibility Study f SAHA Cmbined with Istretinin and Chemtherapy in Infants with Embrynal Tumrs f the Central Nervus System PURPOSE: This clinical trial is studying the side effects f giving
More informationRituxan (rituximab) Effective Date: 10/01/2015. Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Rituxan (rituximab) Line(s) f Business: HMO; PPO; QUEST Integratin Akamai Advantage Effective Date: 10/01/2015 POLICY A. INDICATIONS The indicatins belw including FDA-apprved indicatins and cmpendial uses
More informationGUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH
GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting
More informationCorporate Governance Code for Funds: What Will it Mean?
Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,
More informationBreast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)
Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages
More informationLEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST
OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED
More informationLow Molecular Weight Heparin Prescribing and Administration (Adults)
Clinical guideline Lw Mlecular Weight Heparin Prescribing and Administratin (Adults) The Natinal Patient Safety Agency issued guidance n ways f reducing dsing errrs when prescribing lw mlecular weight
More informationCardiac Rehabilitation Services
Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin
More informationEXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS
1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics
More informationOntario s Referral and Listing Criteria for Adult Lung Transplantation
Ontari s Referral and Listing Criteria fr Adult Lung Transplantatin Versin 2.0 Trillium Gift f Life Netwrk Adult Lung Transplantatin Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The patient referral
More informationP02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017
P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...
More informationProtocol Abstract and Schema
NCI Prtcl #: PBTC-042 Lcal Prtcl #: PBTC-042 Prtcl Abstract and Schema PBTC-042: Phase I study f CDK 4-6 inhibitr PD-0332991 (palbciclib; IBRANCE) in children with recurrent, prgressive r refractry central
More informationTOP TIPS Lung Cancer Update Dr Andrew Wight Consultant respiratory Physician - WUTH
Tpic Circulatin list In case f query please cntact Executive Summary TOP TIPS Lung Cancer Update Dr Andrew Wight Cnsultant respiratry Physician - WUTH All Wirral GP s JaneFletcher2@nhs.net Dear Clleagues,
More informationYescarta (axicabtagene ciloleucel) (Intravenous)
Yescarta (axicabtagene cilleucel) (Intravenus) Last Review Date: 10/31/2017 Date f Origin: 10/31/2017 Dates Reviewed: 10/2017 Dcument Number: IC-0333 I. Length f Authrizatin Cverage will be prvided fr
More informationA pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.
NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting
More informationStructured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information
Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in
More informationEAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL
EAGLE CARE A SPORT CLUB CONCUSSION MANAGEMENT MODEL Cncussin awareness has increased significantly in recent years. The Natinal Cllegiate Athletic Assciatin (NCAA), Natinal Athletic Trainers Assciatin
More informationWound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018
Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered
More informationImplementation of G6PD testing and radical cure in P. vivax endemic countries: considerations
Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines
More informationReferral Criteria: Inflammation of the Spine Feb
Referral Criteria: Inflammatin f the Spine Feb 2019 1 5.7. Inflammatin f the Spine Backgrund Ankylsing spndylitis and axial spndylarthrpathy are fund in arund 0.3-1.2% f the ppulatin. Spndylarthritis encmpasses
More informationDonor Lymphocyte Infusion for Malignancies Treated with an AllogeneicHematopoietic Stem-Cell Transplant
Medical Plicy 2.03.03 Dnr Lymphcyte Infusin fr Malignancies Treated with an AllgeneicHematpietic Stem-Cell Transplant Sectin 2.0 Medicine Subsectin 2.03 Onclgy Effective Date September 30, 2014 Original
More informationDrug Therapy Guidelines
Applicable* Medical Benefit x Effective: 2/15/19 Pharmacy- Frmulary 1 Next Review: 12/19 Pharmacy- Frmulary 2 Date f Origin: 4/1/05 Pharmacy- Frmulary 3/Exclusive Review Dates: 4/1/05, 2/1/06, 10/15/06,
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Orencia (abatacept) Applicable Medical Benefit x Effective: 2/21/18 Pharmacy- Frmulary 1 x Next Review: 12/18 Pharmacy- Frmulary 2 x Date f Origin: 11/28/06 Pharmacy- Frmulary 3/Exclusive
More informationMethadone Maintenance Treatment for Opioid Dependence
POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
(Sanfi-Aventis France), NT001 Suppliers submissin f the SRA apprved text Octber 2016 Name f the medicinal prduct Text bx PACKAGE LEAFLET: INFORMATION FOR THE USER NOTEZINE 100 mg, scred tablets Diethylcarbamazine
More informationSECTION O. MEDICATIONS
SECTION O. MEDICATIONS 1. NUMBER OF MEDICA TIONS (Recrd the number f different medicatins used in the last 7 days; enter "0" if nne used) O1. Number f Medicatins (7-day lk back) Intent: Prcess: Cding:
More informationErythropoiesis Stimulating Agents (ESAs): Aranesp (darbepoetin alfa) Related Medical Guideline Off-Label Use of FDA-Approved Drugs and Biologicals
(Subcutaneus/Intravenus) Last Review Date: January 1, 2019 Number: MG.MM.PH.80 *NON-DIALYSIS* Medical Guideline Disclaimer C All rights reserved. The treating physician r primary care prvider must submit
More informationDRAFT Policy for the Management of Ear Wax
Clinical Cmmissining Grup (CCG) Treatment Plicy NHS Birmingham and Slihull Clinical Cmmissining Grup NHS Sandwell and West Birmingham Clinical Cmmissining Grup DRAFT Plicy fr the Management f Ear Wax 1
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationCompleting the NPA online Patient Safety Incident Report form: 2016
Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject
More informationSUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY
EUROPEAN SOCIETY OF GYNAECOLOGICAL ONCOLOGY SUBSPECIALIST TRAINING PROGRAMME in GYNAECOLOGICAL ONCOLOGY Sme 50% f cancers that affect wmen are lcated in the breast r in the genital rgans. Gynaeclgical
More informationChimeric Antigen Receptor T cell Therapy (CAR-T)
Applies t all prducts administered r underwritten by Blue Crss and Blue Shield f Luisiana and its subsidiary, HMO Luisiana, Inc.(cllectively referred t as the Cmpany ), unless therwise prvided in the applicable
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Louisiana Healthcare Connections Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Luisiana Healthcare Cnnectins Prviders Questin GENERAL Why did Luisiana Healthcare Cnnectins implement a Medical Prgram? Answer
More informationBenefits for Anesthesia Services for the CSHCN Services Program to Change Effective for dates of service on or after July 1, 2008, benefit criteria
Benefits fr Anesthesia Services fr the CSHCN Services Prgram t Change Effective fr dates f service n r after July 1, 2008, benefit criteria fr anesthesia will change fr the Children with Special Health
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQs) For Managed Health Services (MHS)
Questin GENERAL Why did MHS implement a Medical Specialty Slutins Prgram? Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQs) Fr Managed Health Services (MHS) Answer Effective Nvember
More informationSURGICAL NOTE. Surgical Recommendations to Optimize Femoral/Iliac Artery Cannulation
SURGICAL NOTE Surgical Recmmendatins t Optimize Femral/Iliac Artery Cannulatin Due t its size, lcatin, and ease f access, the femral artery is frequently used fr bld pressure catheter placement. Less frequently,
More informationRate Lock Policy. Contents
Rate Lck Plicy Cntents Rate Lcks... 2 Rate Lck Cnfirmatin... 2 Lck Term... 2 Pre-Lck... 2 Maximum Qualified Rate... 3 Extensins... 3 Cst t Extend... 3 Relcks... 4 Re-Negtiatin r Flat Dwn Plicy... 4 Prgram
More informationQ 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?
updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health
More informationReference: Patient A. Brenda WXXXXX Date of Birth: 4/15/57
Reference: Patient A Brenda WXXXXX Date f Birth: 4/15/57 49 year ld white female patient presented n July 20, 2006 with chief cmplaint f stage 4 cancer, initially diagnsed in Octber, 2003 with Cervical
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Apprved by the Bedfrdshire and Lutn Jint Prescribing Cmmittee (JPC) December 2013, Review date December 2016 Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring
More informationShared Care Protocol for the prescribing and monitoring of maintenance doses of azathioprine in Inflammatory Bowel Disease
Bedfrdshire and Lutn Jint Prescribing Cmmittee Shared Care Prtcl fr the prescribing and mnitring f maintenance dses f azathiprine in Inflammatry Bwel Disease This prtcl applies t patients under the care
More informationCSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009
CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral
More informationAppendix C. Master of Public Health. Practicum Guidelines
Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum
More informationACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.
27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000
More informationVaccine Information Statement: LIVE INTRANASAL INFLUENZA VACCINE
Vaccine Infrmatin Statement: LIVE INTRANASAL INFLUENZA VACCINE Many Vaccine Infrmatin Statements are available in Spanish and ther languages. See www.immunize.rg/vis. Hjas de Infrmacián Sbre Vacunas están
More informationInternational Myeloma Working Group Guidelines on Imaging Techniques in the Diagnosis and Monitoring of Multiple Myeloma 1
Internatinal Myelma Wrking Grup Guidelines n Imaging Techniques in the Diagnsis and Mnitring f Multiple Myelma 1 Up t 90% f myelma patients develp stelytic lesins, a majr cause f mrbidity and mrtality,
More informationIndications and Limitations of Coverage and/or Medical back to top
Fr services perfrmed n r after 09/15/2009 Original Determinatin Ending Date Revisin Effective Date Revisin Ending Date Indicatins and Limitatins f Cverage and/r Medical Necessity Indicatins Medicare cverage
More informationConsensus Recommendations for the Management of Chronic Lymphocytic Leukemia: Primary Care Guideline
Practice Guideline: Clinical Guide Cnsensus Recmmendatins fr the Management f Chrnic Lymphcytic Leukemia: Primary Care Guideline CCMB Practice Guideline Clinical Guide Develped by: Lymphprliferative Disrders
More informationDiphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Polio-Haemophilus Influenzae type b Conjugate Combined Vaccine Biological Page (DTaP-IPV-Hib-HB)
Diphtheria-Tetanus-Acellular Pertussis-Hepatitis B-Pli-Haemphilus Influenzae type b Cnjugate Cmbined Vaccine Bilgical Page (DTaP-IPV-Hib-HB) Sectin 7: Bilgical Prduct Infrmatin Standard #: 07.214 Created
More informationDrug Therapy Guidelines
Applicable Medical Benefit x Effective: 5/1/18 Pharmacy- Frmulary 1 x Next Review: 3/18 Pharmacy- Frmulary 2 x Date f Origin: 4/99 Gnadtrpin-Releasing Hrmne Agnists- Eligard, Luprn, Luprn-Dept, Luprn Dept-Ped,
More informationUS Public Health Service Clinical Practice Guidelines for PrEP
Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S
More informationNumber: III-10 Effective Date: Feb 1999
Apprved By: Prvincial Systemic Prgram Cmmittee Revisin Date: Nv 1, 2016; Nv 30, 2017 Page 1 f 11 DIRECTIVE: In rder t ensure the safe prescribing, preparatin, dispensing and administratin f all systemic
More informationAssessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams
Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.
More informationWHAT IS HEAD AND NECK CANCER FACT SHEET
WHAT IS HEAD AND NECK CANCER FACT SHEET This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice
More informationPolicy Guidelines: Genetic Testing for Carrier Screening and Reproductive Planning
Plicy Guidelines: Genetic Testing fr Carrier Screening and Reprductive Planning Cntents Overview... 1 Cverage guidelines... 2 General cverage guidelines... 2 Rutine carrier screening... 2 Carrier screening
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is
More informationHealth Consumers Queensland submission
Health Cnsumers Queensland submissin Inquiry int Public Health (Medicinal Cannabis) Bill 2016 Queensland Parliament Health, Cmmunities, Disability Services and Family Vilence Preventin Cmmittee Cntact:
More informationStrategic Plan Publication No: EO-SP
Strategic Plan 2017-2019 Publicatin N: EO-SP-170223 +61 2 9036 5002 www.pcg.rg.au pcg.ffice@sydney.edu.au This dcument was prepared by the PCG Executive Office PCG Publicatin number: EO-SP-170223 Psych-nclgy
More informationChildhood Immunization Status (NQF 0038)
Childhd Immunizatin Status (NQF 0038) EMeasure Name Childhd Immunizatin EMeasure Id Pending Status Versin Number 1 Set Id Pending Available Date N infrmatin Measurement Perid January 1, 20xx thrugh December
More informationEXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION
EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member
More informationPublic consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking
Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment
More informationProgramme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport
Prgramme f Learning Physical Educatin Key Stage 4 Year 10 BTEC Sprt BTEC Sprt Level 2 Unit 1Fitness fr Sprt and Exercise... 2 Learning aim A: Knw abut the cmpnents f fitness and the principles f training...
More informationOTHER AND UNSPECIFIED DISORDERS
OPTUM COVERAGE DETERMINATION GUIDELINE OTHER AND UNSPECIFIED DISORDERS Guideline Number: BH727OUD_102017 Effective Date: Octber, 2017 Table f Cntents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationALCAT FREQUENTLY ASKED QUESTIONS
1. Is fasting required befre taking the Alcat Test? N. It is recmmended t drink water and t avid stimulants like caffeine prir t the test. 2. With regard t testing children, must a child be a certain age
More informationCDC Influenza Technical Key Points February 15, 2018
CDC Influenza Technical Key Pints In this dcument: Summary Key Pints U.S. Vaccine Effectiveness U.S. Flu Activity Update Summary Key Pints On Thursday, tw influenza-related reprts appeared in the Mrbidity
More informationAppendix C Guidelines for treating status epilepticus in adults and children
Appendix C Guidelines fr treating status epilepticus in adults and children 1.1 Treating cnvulsive status epilepticus in adults General measures 1st stage (0 10 minutes) Secure airway and resuscitate Administer
More informationTick fever is a cattle disease caused by any one of the following blood parasites:
Tick fever Tick fever is a cattle disease caused by any ne f the fllwing bld parasites: Babesia bvis Babesia bigemina Anaplasma marginale These parasites are all transmitted by the cattle tick (Bphilus
More informationNational Imaging Associates, Inc. (NIA) Frequently Asked Questions (FAQ s) For PA Health & Wellness Providers
Natinal Imaging Assciates, Inc. (NIA) Frequently Asked Questins (FAQ s) Fr PA Health & Wellness Prviders Questin GENERAL Why is PA Health & Wellness implementing a Medical Specialty Slutins Prgram? Answer
More informationKent and Medway Policy Recommendation and Guidance Committee Policy Recommendation
Kent and Medway Plicy Recmmendatin and Guidance Cmmittee Plicy Recmmendatin Plicy: PR 2017-11: Surgery fr haemrrhids Issue date: July 2017 Review date: July 2020 The Kent and Medway Plicy Recmmendatin
More informationXX Abraxane 100 MG SUSR (CELGENE CORP)
Plicy Medical Plicy Manual Apprved: D Nt Implement Until 1/31/19 Paclitaxel (Prtein-Bund) NDC CODE(S) 68817-0134-XX Abraxane 100 MG SUSR (CELGENE CORP) DESCRIPTION Paclitaxel is a natural prduct with antitumr
More informationUrinary tract infection (lower) - women - Management
Urinary tract infectin (lwer) - wmen - Management Scenari: Cystitis in wmen wh are nt pregnant Hw shuld I manage a wman with suspected cystitis? Cnvey a psitive apprach and reassure the wman that cystitis
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable* Hereditary Angiedema (HAE) Agents: Berinert (C1 esterase inhibitr [human]), Cinryze (C1 esterase inhibitr [human]), Haegarda (C1 esterase inhibitr [human]) Kalbitr (ecallantide),
More informationSUFFOLK COUNTY COUNCIL. Anti- Social Behaviour Act Penalty Notice. Code of conduct
SUFFOLK COUNTY COUNCIL Anti- Scial Behaviur Act 2003 Penalty Ntice Cde f cnduct SCC Penalty Ntice Cde f Cnduct & Administrative Guidance: revised August 2014 1 Cntents 1. Legal Basis 2. Purpse f the Penalty
More informationTraining module 1: Summary
Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 1: Summary Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking
More informationHealth Screening Record: Entry Level Due: August 1st MWF 150 Entry Year
Health Screening Recrd: Entry Level MIDWIFERY EDUCATION PROGRAM HEALTH SCREENING REQUIREMENTS (Rev. June 2017) 1. Hepatitis B: Primary vaccinatin series (3 vaccines 0, 1 and 6 mnths apart), plus serlgic
More information